Aralez Pharma (ARLZ) Tops Q3 EPS by 5c; Boosts FY16 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARLZ Hot Sheet
Join SI Premium – FREE
Aralez Pharma (NASDAQ: ARLZ) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $136 million versus the consensus estimate of $12.23 million.
GUIDANCE:
Aralez Pharma sees FY2016 revenue of $54-62 million, versus prior guidance of $48-58 million and the consensus of $47.1 million.
For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Capri Holdings Limited (CPRI) Tops Q2 EPS by 21c; offers guidance
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
